title: Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting.
authors.forename: Marco
authors.initials: M
authors.lastname: Vergine
authors.forename: Matteo
authors.initials: M
authors.lastname: Brunelli
authors.forename: Guido
authors.initials: G
authors.lastname: Martignoni
authors.forename: Eleonora
authors.initials: E
authors.lastname: Brunello
authors.forename: Keith
authors.initials: K
authors.lastname: Miller
authors.forename: Sara
authors.initials: S
authors.lastname: Pecori
authors.forename: Samantha
authors.initials: S
authors.lastname: Bersani
authors.forename: Marco
authors.initials: M
authors.lastname: Chilosi
authors.forename: Fabio
authors.initials: F
authors.lastname: Menestrina
authors.forename: Erminia
authors.initials: E
authors.lastname: Manfrin
authors.forename: Franco
authors.initials: F
authors.lastname: Bonetti
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000378:metabolism* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D046888:Tissue Array Analysis; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human